Pharvaris N.V. (PHVS)
NASDAQ: PHVS
· Real-Time Price · USD
17.75
-0.73 (-3.95%)
At close: May 01, 2025, 3:56 PM
17.85
0.54%
After-hours: May 01, 2025, 04:00 PM EDT
-3.95% (1D)
| Bid | 17.16 |
| Market Cap | 967.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -134.22M |
| EPS (ttm) | -2.81 |
| PE Ratio (ttm) | -6.32 |
| Forward PE | -5.54 |
| Analyst | Buy |
| Ask | 18.38 |
| Volume | 49,449 |
| Avg. Volume (20D) | 60,037 |
| Open | 18.27 |
| Previous Close | 18.48 |
| Day's Range | 17.21 - 18.56 |
| 52-Week Range | 11.51 - 25.50 |
| Beta | -2.84 |
About PHVS
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 108
Stock Exchange NASDAQ
Ticker Symbol PHVS
Website https://pharvaris.com
Analyst Forecast
According to 6 analyst ratings, the average rating for PHVS stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 147.82% from the latest price.
Stock Forecasts
